New heart valve registry aims to improve safety and outcomes
NCT ID NCT07343674
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This registry is following 500 adults in Portugal who have severe aortic stenosis and are getting a new type of heart valve replacement called the Medtronic Evolut FX+ TAVI system. The goal is to see if using a standardized procedure makes the treatment safer and more effective. Participants will be checked during their hospital stay, at 30 days, and at one year to track recovery, valve function, and any complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Medtronic Evolut™ FX+ TAVI System (a device for replacing the aortic valve without open-heart surgery)
What this could lead to
If successful, this could help standardize the TAVI procedure to improve safety and reduce complications like the need for a pacemaker.
What could go wrong
This is an observational registry, not a controlled trial, so results may not prove cause and effect. Risks include procedural complications, need for a pacemaker, or valve problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE SYMPTOMATIC AORTIC STENOSIS (DEFINED AS NEW YORK HEART ASSOCIATION (NYHA) CLASS ≥ II) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospitais da Universidade de Coimbra
NOT_YET_RECRUITINGCoimbra, Coimbra District, 3004-561, Portugal
Contact Email: •••••@•••••
Contact
-
Hospital CUF Tejo
NOT_YET_RECRUITINGLisbon, Lisbon District, 1350-352, Portugal
Contact Email: •••••@•••••
Contact
-
Hospital Dr. Nélio Mendonça
NOT_YET_RECRUITINGFunchal, Madeira, 9004-514, Portugal
Contact Email: •••••@•••••
Contact
-
Hospital Eduardo Santos Silva
NOT_YET_RECRUITINGVila Nova de Gaia, Vila Nova de Gaia, 4434-502, Portugal
Contact Email: •••••@•••••
Contact
-
Hospital Lusíadas Lisboa
NOT_YET_RECRUITINGLisbon, Lisbon District, 1500-458, Portugal
Contact Email: •••••@•••••
Contact
-
Hospital Santa Maria
RECRUITINGLisbon, Lisbon District, 1649-035, Portugal
Contact Email: •••••@•••••
Contact
-
Hospital Santa Marta
RECRUITINGLisbon, Lisbon District, 2855-697, Portugal
Contact Email: •••••@•••••
Contact
-
Hospital Universitário de São João
RECRUITINGPorto, Porto District, 4200-319, Portugal
Contact Email: •••••@•••••
Contact
-
Hospital da Luz Coimbra
NOT_YET_RECRUITINGCoimbra, Coimbra District, 3020-479, Portugal
Contact Email: •••••@•••••
Contact
-
Hospital da Luz Lisboa
NOT_YET_RECRUITINGLisbon, Lisbon District, 1500-650, Portugal
Contact
Contact Email: •••••@•••••
-
Hospital de Santa Cruz
RECRUITINGLisbon, Lisbon District, 1449-005, Portugal
Contact Email: •••••@•••••
Contact
-
Hospital do Espírito Santo de Évora
NOT_YET_RECRUITINGEvora, Évora District, 7000-811, Portugal
Contact Email: •••••@•••••
Contact